From Bio Co., Ltd.

As of June 30, 2026, From Bio Co., Ltd. carries a market capitalization of 15.71B, placing it among publicly traded companies globally. Its enterprise value stands at 48.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, From Bio Co., Ltd. has 5.66M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.18, and the price-to-book ratio stands at 0.68.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.68 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 48.43B versus a market cap of 15.71B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, From Bio Co., Ltd. maintains a current ratio of 0.40, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 167.16, indicating elevated leverage, while an interest coverage ratio of -8.98 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, From Bio Co., Ltd. posted a negative return on equity (ROE) of -60.62, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -29.02, reflecting losses generated across the asset base. The company generates approximately 480.80M in revenue per employee across its workforce of 149.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.96 indicates how many times From Bio Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, From Bio Co., Ltd.'s stock has declined approximately 69.42% over the past 52 weeks. The 50-day moving average sits at 2,654.04, while the 200-day moving average is 5,060.91.

Over the twelve months ended June 30, 2026, From Bio Co., Ltd. generated 71.64B in revenue and converted that into -20.13B in net income, yielding earnings per share of -4,532.03. EBITDA reached -14.35B, while operating income came in at -16.28B.

As of June 30, 2026, From Bio Co., Ltd. holds 763.78M in cash and equivalents against 35.47B in total debt, resulting in a net debt position of 34.31B. Total book value stands at 23.20B, with working capital of -22.12B providing operational flexibility.

From Bio Co., Ltd. produced -7.76B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -822.58M in capital expenditures, free cash flow totaled -8.58B - equivalent to -1,893.98 per share.

Over the twelve months ended June 30, 2026, From Bio Co., Ltd. posted a gross margin of 62.96, reflecting its pricing power and cost economics. The operating margin of -22.73 and net profit margin of -28.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -68.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.17, meaning From Bio Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

From Bio Co., Ltd.'s most recent stock split took place on August 10, 2026 with a 5:1 split ratio.

As of June 30, 2026, From Bio Co., Ltd. has an Altman Z-Score of -0.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.